NCT00508144View on ClinicalTrials.gov

Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Lung Cancer
Interventions
DRUG

Alimta

500 mg/m\^2 by vein Once Over 10 Minutes Every 3 Weeks

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00508144 - Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter